Updates are available Correction dated 2022-04-06
Click to view Correction: https://doi.org/10.1038/s41564-022-01118-8
-
Authors
Aggarwala, Varun
Mogno, Ilaria
Li, Zhihua
Yang, Chao
Britton, Graham J. https://orcid.org/0000-0003-4630-1223
Chen-Liaw, Alice
Mitcham, Josephine
Bongers, Gerold
Gevers, Dirk
Clemente, Jose C. https://orcid.org/0000-0002-3970-9856
Colombel, Jean-Frederic
Grinspan, Ari
Faith, Jeremiah https://orcid.org/0000-0002-2691-4500
- License Information
-
More Information
Article History
Received: 28 June 2021
Accepted: 20 August 2021
First Online: 27 September 2021
Change Date: 6 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41564-022-01118-8
Competing interests
: J.F. is on the scientific advisory board of Vedanta Biosciences, reports receiving research grants from Janssen Pharmaceuticals and reports receiving consulting fees from Innovation Pharmaceuticals, Janssen Pharmaceuticals, BiomX and Vedanta Biosciences. J.-F.C. reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda, receiving payment for lectures from AbbVie, Amgen, Allergan, Bristol Myers Squibb, Ferring Pharmaceuticals, Shire and Takeda, receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Celltrion Healthcare, Eli Lilly, Enterome, Ferring Pharmaceuticals, Geneva Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Imedex, Immunic, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka Pharmaceutical, Pfizer, Shire, Takeda, TiGenix and Viela Bio and holds stock options in Intestinal Biotech Development. D.G. is an employee of Janssen Research and Development. The other authors declare no competing interests. A patent has been filed on this work (Patent Cooperation Treaty application PCT/US21/71018, filed 27 July 2021).
